$0.17
−0.06%Price chart
Aug 24Aug 28Sep 2Sep 11Sep 22Sep 29Oct 14Oct 19
Key dataOct 19, 2026
Open$2.10
From 52W high−95.95%
Volume12990.00
Market cap$8.69M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$2.10
From 52W high
−95.95%
Volume
12990.00
Market cap
$8.69M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.7x
P/E (TTM)
—
RSI (14)
44.9
MomentumView details →
1D Return
−0.06%
YTD Return
−94.59%
SummaryUpdated Jul 1, 2026
enGene Holdings Inc. (NASDAQ:ENGNW) is a clinical-stage biotechnology company founded in 2023 and headquartered in Saint-Laurent, Canada. The company operates through its subsidiary enGene, Inc., and focuses on developing genetic medicines delivered to mucosal tissues and other organs. As a recently established biotech firm, enGene is currently in the clinical development phase with no commercial revenue, dedicating its resources to advancing its lead therapeutic candidate through regulatory trials for cancer treatment.
Similar companies
Latest newsMore news →
enGene Therapeutics Inc. reported its Q3 2026 financial results, with a net loss of $32.5 million and diluted EPS of -$0.47, and cash and marketable securities of $266.3 million.42d agoRichard Glickman resigned as director and chairman of the Board of Directors of enGene Therapeutics Inc., effective July 15, 2026.96d ago